The global pharmaceutical industry is witnessing a surge in innovation, with the industry experiencing a 5% growth in the number of AI-related patent applications in Q1 2024 and
The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.